<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00446979</url>
  </required_header>
  <id_info>
    <org_study_id>CDC-NCHHSTP-4744</org_study_id>
    <secondary_id>MOPH 109/2548</secondary_id>
    <nct_id>NCT00446979</nct_id>
  </id_info>
  <brief_title>Safety Study of UC-781 Vaginal Microbicide</brief_title>
  <official_title>Phase I Study of the Safety and Acceptability of UC-781 Topical Vaginal Microbicide in Women and Acceptability in Their Male Partners,Chiang Rai, Thailand</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CONRAD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centers for Disease Control and Prevention</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will help determine whether UC-781 gel is safe when applied to the vagina twice
      daily for 14 days, and will assess whether women and men find the gel acceptable to use.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Genital tract inflammation or epithelial disruption as assessed by naked eye and colposcopic inspection according to established guidelines</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptoms of irritation</measure>
    <time_frame>two weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in vaginal flora</measure>
    <time_frame>Two weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of pro-inflammatory cytokines in the genital tract</measure>
    <time_frame>Two weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Other product-related adverse events</measure>
    <time_frame>Two weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>acceptability of UC-781 gel use</measure>
    <time_frame>Two weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>systemic absorption of UC-781</measure>
    <time_frame>Two weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anti-HIV activity of genital secretions in the presence of UC-781 gel</measure>
    <time_frame>Two weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UC 781 0.1% carbomer gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UC 781 0.25% carbomer gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo vaginal gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo gel</intervention_name>
    <description>HEC (hydroxyethyl cellulose) Control Gel applied vaginally twice daily for two weeks</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UC 781</intervention_name>
    <description>UC 781 0.1% or UC 781 0.25%, applied vaginally twice daily for two intermenstrual weeks</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for women:

          -  Age 18-50 years old

          -  Regular menses

          -  HIV-1 seronegative at screening

          -  Normal Pap smear at screening or documented normal Pap smear within six months prior
             to screening

          -  No evidence of reproductive tract infection (RTI)

          -  Willing and able to comply with study procedures, including pelvic exams, colposcopy,
             maintaining a study coital and symptom log, and applying assigned study gel per
             protocol

          -  Agree to abstain from sexual intercourse for 24 hours prior to the enrollment visit

          -  Agree to abstain from the following activities from at least 48 hours prior to
             enrollment through the Day 14 visit:

               -  Insertion of fingers and other objects into the vagina

               -  Receiving oral sex

               -  Receiving anal sex

               -  Using a diaphragm, cervical cap, female condom, or vaginal contraceptive ring

               -  Using vaginal products other than the study gels, including douches, lubricants,
                  or feminine hygiene products

          -  In a monogamous sexually active relationship with one male partner

          -  Report having vaginal intercourse only with that partner at least two times per week

          -  No other reported partner in the prior six months and no plan to have another partner
             for the duration of the study

          -  Agree to use condoms for each act of vaginal intercourse during participation in the
             study

          -  Their male partner is informed and also consents to participate in the study

          -  Willing to have male partner informed and treated if an STD is diagnosed at screening
             or during the study

        Inclusion Criteria for men:

          -  Age 18 years or older

          -  HIV-seronegative and free of other STI at screening exam

          -  One female sexual partner; no other reported partner in the prior six months and no
             plan to have another partner for the duration of the study

          -  Willing and able to comply with study procedures, including clinic visits, interviews
             and acceptability evaluation, and consistent use of condoms during enrollment in the
             study

          -  Willing to have female partner informed and treated if an STD is diagnosed at
             screening or during the study

        Exclusion Criteria for women:

          -  Pregnancy or desire to become pregnant at time of study participation

          -  Currently breastfeeding

          -  Delivery or abortion within last eight weeks

          -  History of any male sexual partner other than current partner in past six months

             - No abnormal (DAIDS grade 1 or higher) laboratory results at baseline, including
             hematology, liver and kidney function

          -  History of post-coital vaginal bleeding in the past three months

          -  History of surgery to remove uterus or cervix

          -  History of surgery on the external genitalia, vaginal, or cervix in the past month

          -  Clinically significant chronic medical condition that is considered progressive,
             including cardiopulmonary disease, renal disease, hepatic disease, diabetes mellitus.

          -  History of sensitivity/allergy to latex

          -  Existence of a clinically detectable genital abnormality at screening (e.g. ulcer,
             congenital abnormality, any lesion with mucosal disruption)

          -  Concurrent participation in another trial of a vaginal product

          -  Have any other condition that in the opinion of the investigator might interfere with
             the evaluation of the study objectives

        Exclusion Criteria for men:

          -  History of genital surgery in the past month

          -  Clinical or laboratory evidence of an STI.

          -  History of sensitivity/allergy to latex

          -  History of any sexual partner other than their current partner in the past six months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara J Whitehead, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chitlada Utaipiboon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thailand MOPH - U.S. CDC Collaboration</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chiang Rai Health Club</name>
      <address>
        <city>Chiang Rai</city>
        <zip>57000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2007</study_first_submitted>
  <study_first_submitted_qc>March 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2007</study_first_posted>
  <last_update_submitted>April 18, 2013</last_update_submitted>
  <last_update_submitted_qc>April 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Microbicides</keyword>
  <keyword>HIV seronegativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Infective Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

